A key objective of the Medicines Patent Pool’s licence agreements is to help improve access to safe, effective, more appropriate and affordable essential medicines in low- and middle-income countries, by reducing prices, improving supplies or adding capacity.
You are a patent holder working on essential medicines and would like to know more about our licensing mechanism for public health and how it could benefit your company.
The Medicines Patent Pool is the first patent pool with a clear public health mandate, established by Unitaid in 2010. MPP operates as a non-profit voluntary licensing mechanism through partnerships with originator pharmaceutical companies and generic manufacturers that facilitate access and promote innovation.
What MPP has to offer:
- Direct support to licensors: MPP offers tangible actions and services, namely the management of licensees and information provision.
- Increased knowledge: insight into disease areas in countries where the originator presence is absent or reduced. MPP works with governments, the World Health Organization and other international public health agencies and stakeholders and can contribute to a better understanding of the global health area.
- Reputational impact: as access becomes more and more important, innovators can be seen to make a concrete contribution to supporting access through a mechanism with a proven track record.
Together with MPP, sustainable access to effective and affordable innovative quality-assured treatments administered in resource-limited settings can become a reality.
Please contact our business development team to discuss how we could work together: firstname.lastname@example.org
You are a generic manufacturer and would like to develop, manufacture and supply MPP’s licensed products:
- MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of the 11 NIH technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
- MPP invites interested manufacturers based anywhere in the world to express their interest in obtaining a sublicence for the ELISA antibody technology (COVID-19 diagnostic test) by submitting a single email to CTAPDiagnostics@medicinespatentpool.org with complete, detailed responses to the questionnaire provided here.
- MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for MVA-S(3P) (Vaccine Candidate) by submitting an e-mail to C-TAPvaccines@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
- MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for Vaccine MVC-COV1901 by submitting an e-mail to C-TAPvaccines@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
- MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for Technology that detects the presence of neutralising antibodies against SARS-CoV-2 by submitting an e-mail to CTAPDiagnostics@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
We invite qualified product developers to apply for licences to manufacture and sell licensed treatments in low- and middle-income countries. We do this through an Expression of Interest (EOI) process. By granting multiple sublicences, we aim to encourage adequate sources of supply, and competitive pricing models.
If you wish to apply, you should complete an online Expression of Interest (EOI) form, which serves as your proposal to use our licensed intellectual property to create or improve access to relevant medicines in countries enabled by the licence.
You will need to provide details of your capacity, capabilities and track-record for manufacturing quality-assured medicines, your R&D, regulatory compliance and financials. You should also provide specific plans for the products you wish to license. These should cover development, manufacturing, regulatory plan, distribution and predicted investments. Among other criteria, we will consider your organisation’s state of readiness with needed formulations, including fixed-dose combinations and paediatric formulations.
Our EOI form has two sections. One is about your organisation and the second concerns your state of readiness and plans for the products and licence in question. You do not need to complete the first section more than once; you can update it as needed. The second section is specific to each licence, so you should complete it for each separate application.
Method for granting sublicences
The EOI assessment is rigorous and objective and follows a two-stage process. A panel assesses each EOI and the final decision makers do not know the applicant’s identity. Each question carries a weighting and a maximum score. Responses are graded using a standardised tool and top-scoring applicants are selected. The number of licences we grant is based on WHO-MPP forecasts for the product in question. Criteria such as viability of development plans (especially in case of projects requiring specific capital expenditure or investments), quality and past performance (especially in case of serious breaches of voluntary licence agreements) may result in us rejecting an application.
For accurate assessment, we encourage applicants to provide as much detail as possible to ensure the EOI represents their actual capacities, capabilities and plans. Incomplete EOIs risk rejection.
In line with our mandate to promote local manufacturing in developing countries, we also encourage applications from qualified manufacturers for servicing demand in a limited region or selected countries.
EOIs usually open immediately after we announce that we have obtained a patent licence from a patent holder, and there is normally a three to four weeks period to apply online. If you have any queries regarding the process or specific questions on the EOI form, please email email@example.com.
We will not disclose or use any commercial and technical information we receive in EOIs for any purpose other than assessment. We will always ask you for permission to use your details for any other purpose.
Companies not approved will be offered an explanation on why they were not selected. Companies may appeal to the MPP Board within 14 calendar days if they wish to challenge the decision made in the EoI process. The grounds for appeal are (a) the EoI process was not followed by MPP or (b) critical new information that would have led to a significantly different outcome in the EoI assessment has become available that was not available when the EoI was submitted.